Cálculo de la eficiencia de oportunidad de los nuevos medicamentos

作者: Javier Soto Álvarez

DOI: 10.1007/BF03320905

关键词:

摘要:

参考文章(14)
MarkJ.C. Nuijten, Joszef Kosa, Pricing of pharmaceuticals. Assessing the pricing potential by a pricing matrix model. European Journal of Health Economics. ,vol. 5, pp. 110- 115 ,(2004) , 10.1007/S10198-003-0209-Y
Stephen Birch, Amiram Gafni, Cost effectiveness/utility analyses. Do current decision rules lead us to where we want to be? Journal of Health Economics. ,vol. 11, pp. 279- 296 ,(1992) , 10.1016/0167-6296(92)90004-K
A. Gafni, S. Birch, Guidelines for the adoption of new technologies: a prescription for uncontrolled growth in expenditures and how to avoid the problem Canadian Medical Association Journal. ,vol. 148, pp. 913- 917 ,(1993)
Göran Karlsson, Magnus Johannesson, The decision rules of cost-effectiveness analysis. PharmacoEconomics. ,vol. 9, pp. 113- 120 ,(1996) , 10.2165/00019053-199609020-00003
George W. Torrance, David Blaker, Allan Detsky, Wendy Kennedy, Francois Schubert, Devidas Menon, Peter Tugwell, Richard Konchak, Eleanor Hubbard, Theresa Firestone, Canadian Guidelines for Economic Evaluation of Pharmaceuticals PharmacoEconomics. ,vol. 9, pp. 535- 559 ,(1996) , 10.2165/00019053-199609060-00008
Pedram Sendi, Maiwenn J. Al, Revisiting the decision rule of cost-effectiveness analysis under certainty and uncertainty. Social Science & Medicine. ,vol. 57, pp. 969- 974 ,(2003) , 10.1016/S0277-9536(02)00477-X
Magnus Johannesson, Richard M. O'Conor, Cost-utility analysis from a societal perspective Health Policy. ,vol. 39, pp. 241- 253 ,(1997) , 10.1016/S0168-8510(96)00878-0
J.-M. Graf von der Schulenburg, C. Hoffmann, Review of European guidelines for economic evaluation of medical technologies and pharmaceuticals Hepac Health Economics in Prevention and Care. ,vol. 1, pp. 2- 8 ,(2000) , 10.1007/S101980050002